Chi-Med Reports 2018 Interim Results and Updates Shareholders on Key Clinical Programs
July 27, 2018 02:00 ET
|
Hutchison China MediTech Limited
LONDON, July 27, 2018 (GLOBE NEWSWIRE) -- Hutchison China MediTech Limited (“Chi-Med”) (AIM:HCM) (Nasdaq:HCM) today announces its unaudited financial results for the six months ended June 30, 2018...
Chi-Med Initiates a Phase Ib/II Proof-of-Concept Trial of Sulfatinib in Pancreatic Neuroendocrine Tumors and Biliary Tract Cancer in the United States
July 23, 2018 02:00 ET
|
Hutchison China MediTech Limited
LONDON, July 23, 2018 (GLOBE NEWSWIRE) -- Hutchison China MediTech Limited (“Chi-Med”) (AIM:HCM) (Nasdaq:HCM) has initiated a Phase Ib/II proof-of-concept study of sulfatinib in pancreatic...
Chi-Med to Announce 2018 Half-Year Financial Results
June 29, 2018 02:00 ET
|
Hutchison China MediTech Limited
LONDON, June 29, 2018 (GLOBE NEWSWIRE) -- Hutchison China MediTech Limited (“Chi-Med”) (AIM:HCM) (Nasdaq:HCM) will be announcing its interim results for the six months ended June 30, 2018 on Friday,...
Chi-Med Presents Further Fruquintinib FRESCO Trial Data at ASCO 2018 Annual Meeting
June 04, 2018 04:51 ET
|
Hutchison China MediTech Limited
– Chi-Med makes additional FRESCO presentations at ASCO 2018, following oral presentation at ASCO 2017 showing that study met all endpoints with a manageable safety profile and lower off-target...
Chi-Med to Present at Bank of America Merrill Lynch Annual Health Care Conference
May 11, 2018 07:34 ET
|
Hutchison China MediTech Limited
LONDON, May 11, 2018 (GLOBE NEWSWIRE) -- Hutchison China MediTech Limited (“Chi-Med”) (AIM:HCM) (Nasdaq:HCM) announced today that Christian Hogg, Chief Executive Officer, will present at the Bank of...